 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In the second quarter of FY24, the Pharma stocks saw strong revenue growth of 14.3% year-over-year and 1.7% quarter-over-quarter

Nifty Pharma scales record highs, rises in 14 out of 17 straight sessions

Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones

Torrent and Zydus sign pact to co-market Saroglitazar for chronic liver diseases in India

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 687 in its research report dated November 06, 2023.

Buy Zydus Lifesciences; target of Rs 687 Sharekhan

Motilal Oswal recommended Neutral rating on Zydus LifeSciences with a target price of Rs 660 in its research report date November 07, 2023.

Neutral Zydus LifeSciences; target of Rs 660: Motilal Oswal

Zydus Life Consolidated September 2023 Net Sales at Rs 4,368.80 crore, up 5.66% Y-o-Y

Zydus Life Standalone September 2023 Net Sales at Rs 2,159.30 crore, down 9.98% Y-o-Y

Zydus Life posts 53.2% surge in Q2 net profit to Rs 800.7crore

Zydus added that LiqMeds Group has capabilities and specialisation in development, manufacturing and supply of oral liquid products for global markets, which it currently commercializes through partners.

﻿Zydus Life to acquire LiqMeds Group for Rs 689 crore

Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease in India.

Zydus, Sun Pharma to co-market oral drug for anaemia linked to kidney diseases

Zydus Lifesciences on October 20 announced that the USFDA approved its New Drug Application (NDA) for ZITUVIOTM (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, company said in its statement.

Zydus Lifesciences gain on US FDA approval for diabetic drug

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Watchers	247
52-Wk Low	398.95
52-Wk High	668.75

Market Cap	647.66B
Volume (M)	606,266.00
52-Wk High	668.75
52-Wk Low	398.95

ZYDUSLIFE.NSE Zydus Lifesciences Ltd.

About

Feed

News

Sentiment

Fundamentals

Latest ZYDUSLIFE.NSE News